Proteomics-driven screening of artemisinin-based combination ratios and mechanistic insights into <i>Plasmodium berghei</i> infection in mice.

ABSTRACT:

Introduction

Malaria, a life-threatening mosquito-borne disease caused by Plasmodium falciparum, poses a substantial health burden on tropical and subtropical regions. Artemisinin, a sesquiterpene lactone isolated from Artemisia annua L., and its derivatives were initially used as monotherapies for malaria treatment. However, limitations such as short pharmacokinetic half-life and emerging drug resistance have driven the widespread adoption of artemisinin-based combination therapies (ACTs) as first-line interventions. A. annua contains other bioactive compounds such as arteannuin B, artemisinic acid, and scopoletin that exhibit distinct pharmacological properties. In this study, we aimed to devise a new strategy for treatment of malaria to overcome artemisinin

SUBMITTER: Hao L 

PROVIDER: S-EPMC12715000 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature